Biogen Idec, Drug Discovery, 12 Cambridge Center, Cambridge, MA 02142, USA.
Bioorg Med Chem. 2013 Jul 15;21(14):4011-9. doi: 10.1016/j.bmc.2013.04.019. Epub 2013 Apr 19.
Keap1 binds to the Nrf2 transcription factor to promote its degradation, resulting in the loss of gene products that protect against oxidative stress. While cell-active small molecules have been identified that modify cysteines in Keap1 and effect the Nrf2 dependent pathway, few act through a non-covalent mechanism. We have identified and characterized several small molecule compounds that specifically bind to the Keap1 Kelch-DC domain as measured by NMR, native mass spectrometry and X-ray crystallography. One compound upregulates Nrf2 response genes measured by a luciferase cell reporter assay. The non-covalent inhibition strategy presents a reasonable course of action to avoid toxic side-effects due to non-specific cysteine modification.
Keap1 与 Nrf2 转录因子结合,促进其降解,导致对抗氧化应激的基因产物丢失。虽然已经鉴定出能够修饰 Keap1 中的半胱氨酸并影响 Nrf2 依赖性途径的细胞活性小分子,但很少有通过非共价机制起作用的小分子。我们已经通过 NMR、天然质谱和 X 射线晶体学鉴定和表征了几种能够与 Keap1 Kelch-DC 结构域特异性结合的小分子化合物。一种化合物通过荧光素酶细胞报告基因测定上调 Nrf2 反应基因。非共价抑制策略提供了一种合理的行动方案,可避免由于非特异性半胱氨酸修饰而导致的毒副作用。